Pancreatic cancer is a growing source of cancer-related death and has poor survival rates, which have not improved in the last few decades. Its high-mortality rate is attributed to pancreatic cancer biology and difficulty in early diagnosis. Approximately 20% of patients have a resectable or a borderline resectable cancer at diagnosis. Achieving an R0 resection is the only curative option. Nevertheless, many R0-resected patients will relapse within 2 years from surgery. Neoadjuvant treatment has been explored in order to improve survival. Currently, clinical trials are ongoing, and probably soon this approach will become a standard of care among borderline resectable patients and probably in selected resectable patients too. Theoretical advantages of neoadjuvant treatment include increased R0 resection rate, early delivery of systemic therapy to all patients (addressing occult metastatic disease), and improved patient selection for resection.
We aim to give a general overview of the current treatment strategies for resectable and borderline resectable patients, to discuss the rationale for neoadjuvant therapy, and to consider the surgical challenges and technical aspects in this specific situation.
This Research Topic aims to provide an update on the current state of neoadjuvant treatment in pancreatic cancer and to evaluate the benefits and limitations of the available surgical therapy.
Specific themes:
- Technical advances in surgery for pancreatic cancer: artery first, uncinate first, RAMPS.
- Techniques for vascular resection and reconstruction after neoadjuvant chemotherapy
- Total mesopancreas excision, its significance on local recurrence after neoadjuvant chemotherapy
- MIS Whipple in which patient after neoadjuvant chemotherapy
- Recent progresses in neoadjuvant chemotherapy
- Genetic profiling based surgery for PDAC
- Preoperative treatment of PDAC in the era of precision medicine
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Pancreatic cancer is a growing source of cancer-related death and has poor survival rates, which have not improved in the last few decades. Its high-mortality rate is attributed to pancreatic cancer biology and difficulty in early diagnosis. Approximately 20% of patients have a resectable or a borderline resectable cancer at diagnosis. Achieving an R0 resection is the only curative option. Nevertheless, many R0-resected patients will relapse within 2 years from surgery. Neoadjuvant treatment has been explored in order to improve survival. Currently, clinical trials are ongoing, and probably soon this approach will become a standard of care among borderline resectable patients and probably in selected resectable patients too. Theoretical advantages of neoadjuvant treatment include increased R0 resection rate, early delivery of systemic therapy to all patients (addressing occult metastatic disease), and improved patient selection for resection.
We aim to give a general overview of the current treatment strategies for resectable and borderline resectable patients, to discuss the rationale for neoadjuvant therapy, and to consider the surgical challenges and technical aspects in this specific situation.
This Research Topic aims to provide an update on the current state of neoadjuvant treatment in pancreatic cancer and to evaluate the benefits and limitations of the available surgical therapy.
Specific themes:
- Technical advances in surgery for pancreatic cancer: artery first, uncinate first, RAMPS.
- Techniques for vascular resection and reconstruction after neoadjuvant chemotherapy
- Total mesopancreas excision, its significance on local recurrence after neoadjuvant chemotherapy
- MIS Whipple in which patient after neoadjuvant chemotherapy
- Recent progresses in neoadjuvant chemotherapy
- Genetic profiling based surgery for PDAC
- Preoperative treatment of PDAC in the era of precision medicine
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
